Autologous Mesenchymal Stem Cells Prevent Transplant Arteriosclerosis by Enhancing Local Expression of Interleukin-10, Interferon-γ, and Indoleamine 2,3-dioxygenase
- 1 May 2012
- journal article
- research article
- Published by SAGE Publications in Cell Transplantation
- Vol. 21 (5) , 971-984
Abstract
Transplant arteriosclerosis (TA) remains the major limitation of long-term graft survival in heart transplantation despite the advances in immunosuppressants. Mesenchymal stem cells (MSCs) have been demonstrated to suppress allogeneic immune responses by numerous in vitro studies. However, the immunomodulatory effects of MSCs in vivo are controversial and the underlying molecular mechanisms are not conclusive. In this study, we investigated the therapeutic potential of autologous bone marrow-derived MSCs on TA in a porcine model of femoral artery transplantation. MSCs or saline were injected into the soft tissue surrounding the arterial grafts immediately postanastomosis. Four weeks after transplantation, neointimal formation increased significantly in untreated allografts compared with the MSC-treated grafts as assessed by intravascular ultrasound (maximum luminal area stenosis: 40 ± 12% vs. 18 ± 6%, p < 0.001). Grafts harvested at 4 weeks showed dense perivascular lymphocyte infiltration accompanied by significant intimal hyperplasia in the untreated but not in the MSC-treated allografts. Serial angiographic examination showed that all of the untreated allografts became occluded at the 8th week whereas the majority of the MSC-treated grafts remained patent at the 12th week posttransplantation ( n = 12 each group, p < 0.001). Quantitative PCR analysis revealed that Foxp3 expression was comparable between the untreated and the MSC-treated groups. However, expression of interleukin-10 (IL-10), interferon-γ (IFN-γ), and indoleamine 2,3-dioxygenase (IDO) was increased significantly in the MSC-treated allografts compared with that in the allograft controls ( p = 0.021 for IL-10, p = 0.003 for IFN-γ, and p = 0.008 for IDO). In conclusion, local delivery of autologous MSCs alleviates TA by inducing allograft tolerance via enhanced expression of IL-10, IFN-γ, and IDO but not Foxp3-positive cells in the vessel wall. These results suggest that MSCs induce immune tolerance by activating the type 1 regulatory T-like cells.Keywords
This publication has 28 references indexed in Scilit:
- Syngeneic Bone Marrow Cell Therapy Prevents Intimal Proliferation in Allogeneic Vascular TransplantationJournal of Surgical Research, 2011
- Immunogenicity and Immunomodulatory Properties of Umbilical Cord Lining Mesenchymal Stem CellsCell Transplantation, 2011
- Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study GroupTransplantation, 2009
- Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T CellsThe Journal of Immunology, 2008
- Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantationCurrent Opinion in Organ Transplantation, 2008
- Induction of Indoleamine 2,3-Dioxygenase in Vascular Smooth Muscle Cells by Interferon-γ Contributes to Medial ImmunoprivilegeThe Journal of Immunology, 2007
- Immunologic Consequences of Multiple, High-Dose Administration of Allogeneic Mesenchymal Stem Cells to BaboonsCell Transplantation, 2006
- Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsivenessBlood, 2005
- Human mesenchymal stem cells modulate allogeneic immune cell responsesBlood, 2005
- Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuliBlood, 2002